{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000037","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.569379+00:00","generated_at":"2026-05-15T00:52:46.572228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit Q1 net loss $189.4M, cash $598.7M; ivonescimab OS data at ASCO plenary","bullets":["GAAP net loss $189.4M ($0.24/sh) vs $62.9M ($0.09/sh) YoY; non-GAAP net loss $116.6M ($0.15/sh).","Cash and short-term investments $598.7M, down $114.7M from Dec 2025; cash burn funds ivonescimab trials.","HARMONi-6 (squamous NSCLC in China) OS data to be presented at ASCO 2026 plenary as late-breaking abstract.","HARMONi-3 squamous final PFS expected H2 2026; interim PFS cleared by iDMC, study continues blinded.","BLA for ivonescimab in EGFR-mutated NSCLC accepted; PDUFA date Nov 14, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000037","json":"https://secwatch.observer/filing/0001599298-26-000037.json","markdown":"https://secwatch.observer/filing/0001599298-26-000037.md","text":"https://secwatch.observer/filing/0001599298-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/0001599298-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/smmt-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:52:46.572228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"830492ed69e7b34fa43008c16fe9e63b28ace342","claim":"Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On April 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000037/0001599298-26-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}